Catyalyst Pharmaceutical Partners (NASDAQ: CPRX) reported Q2 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07).

"We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE